Device Trial Radar · NCT06742801
Onyx™ Liquid Embolic IDE Clinical Study
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
119
Planned (sponsor's estimate)
Start
May 9, 2025
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Medtronic EndovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of Onyx™ LES in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.
Conditions
- Peripheral Arterial Hemorrhage
- Trauma
- GI Bleed
- Ulcer
- Hemorrhage
Interventions
Onyx™ Liquid Embolic SystemDevice
The proposed indication for Onyx™ LES is: Onyx™ LES is indicated for the embolization of arterial hemorrhage in the peripheral vasculature.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Freedom from Arterial HemorrhageTime frame: Through 30 days post-index procedure
- Freedom from System-related Major Adverse Events (MAE)Time frame: Through 30 days post-index procedure
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona · Recruiting
University of California, Irvine
Irvine, California · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
17 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.